KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAssetsBuildingsCash & Current InvestmentsCash & EquivalentsCommon EquityConstruction in ProgressCurrent AssetsCurrent TaxesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityNotes PayablesOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Biogen (BIIB) Non-Current Debt (2022 - 2025)

Biogen (BIIB) has 9 years of Non-Current Debt data on record, last reported at $6.3 billion in Q4 2025.

  • For Q4 2025, Non-Current Debt rose 38.26% year-over-year to $6.3 billion; the TTM value through Dec 2025 reached $6.3 billion, up 38.26%, while the annual FY2025 figure was $6.3 billion, 38.26% up from the prior year.
  • Non-Current Debt reached $6.3 billion in Q4 2025 per BIIB's latest filing, up from $4.5 billion in the prior quarter.
  • Across five years, Non-Current Debt topped out at $6.8 billion in Q4 2023 and bottomed at $4.5 billion in Q4 2024.
  • Average Non-Current Debt over 4 years is $6.0 billion, with a median of $6.3 billion recorded in 2022.
  • Peak YoY movement for Non-Current Debt: tumbled 33.01% in 2024, then surged 38.26% in 2025.
  • A 4-year view of Non-Current Debt shows it stood at $6.3 billion in 2022, then grew by 8.08% to $6.8 billion in 2023, then crashed by 33.01% to $4.5 billion in 2024, then soared by 38.26% to $6.3 billion in 2025.
  • Per Business Quant database, its latest 3 readings for Non-Current Debt were $6.3 billion in Q4 2025, $4.5 billion in Q4 2024, and $6.8 billion in Q4 2023.